Editorial Board
(Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 27, 2018 Category: Cancer & Oncology Source Type: research

Critical review of axillary recurrence in early breast cancer
Recurrences after curative treatment in early breast cancer are usually divided into distant and loco-regional recurrence (LRR). Definition of regional recurrence (RR) after surgery includes locations in internal mammary, supraclavicular or infraclavicular lymph nodes, as well as axillary recurrence (AR). Although it had been assumed that AR reflects only insufficient control of the axilla (Smidt et al., 2005; van der Ploeg et al., 2008), the low AR rate even in cases without axilla management suggests that it reflects the absence of an effective immune system activity against remaining involved nodes and an insufficient r...
Source: Critical Reviews in Oncology Hematology - June 23, 2018 Category: Cancer & Oncology Authors: Carlos A. Castaneda, Pamela Rebaza, Miluska Castillo, Henry H. Gomez, Miguel de La Cruz, Gabriela Calderon, Jorge Dunstan, Jose Manuel Cotrina, Julio Abugattas, Tatiana Vidaurre Source Type: research

Do SABR-related toxicities for lung cancer depend on treatment delivery?
Lung cancer is the most common cancer worldwide, both in new cases and deaths (Ferlay et al., 2012). Non-small cell lung carcinomas (NSCLC) account for approximately 60% of all lung cancers and tend to progress in a slower fashion compared to small cell lung carcinomas (SCLC) (approximately 12% of lung cancers) a more aggressive type of lung cancer, known to metastasise to the brain (Kumar et al., 2013). There are several treatment options to be considered for lung cancer patients and they are: surgery (e.g. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 23, 2018 Category: Cancer & Oncology Authors: Stamati Morias, Loredana Gabriela Marcu, Michala Short, Eileen Giles, Eva Bezak Source Type: research

Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
Radiofrequency ablation (RFA) is an effective local treatment for curative intent in patients with cirrhosis of the liver and hepatocellular carcinoma (HCC) with diameter (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 23, 2018 Category: Cancer & Oncology Authors: Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassine Source Type: research

Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients ’ selection
We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 23, 2018 Category: Cancer & Oncology Authors: Giuseppe Luigi Banna, Francesco Passiglia, Francesca Colonese, Stefania Canova, Jessica Menis, Alfredo Addeo, Antonio Russo, Diego Luigi Cortinovis Source Type: research

Ionizing radiation-induced cellular senescence promotes tissue fibrosis after radiotherapy. A review
Ionizing radiation-exposure induces a variety of cellular reactions, such as senescence and apoptosis. Senescence is a permanent arrest state of the cell division, which can be beneficial or detrimental for normal tissue via an inflammatory response and senescence-associated secretion phenotype. Damage to healthy cells and their microenvironment is considered as an important source of early and late complications with an increased risk of morbidity in patients after radiotherapy (RT). In addition, the benefit/risk ratio may depend on the radiation technique/dose used for cancer eradication and the irradiated volume of heal...
Source: Critical Reviews in Oncology Hematology - June 22, 2018 Category: Cancer & Oncology Authors: Hoang Quy Nguyen, Nhu Hanh To, Patricia Zadigue, St éphane Kerbrat, Alexandre De La Taille, Sabine Le Gouvello, Yazid Belkacemi Source Type: research

Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer
Breast cancer (BC) represents the most common cancer and the second cause of cancer-related mortality among women in developed countries. The number of women living with a BC continues to grow, due to advances in early detection and targeted treatment strategies [1]. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 21, 2018 Category: Cancer & Oncology Authors: Ilaria Trestini, Luisa Carbognin, Sara Monteverdi, Sara Zanelli, Alessandro De Toma, Clelia Bonaiuto, Rolando Nortilli, Elena Fiorio, Sara Pilotto, Massimo Di Maio, Antonio Gasbarrini, Giovanni Scambia, Giampaolo Tortora, Emilio Bria Source Type: research

Imaging predictors of treatment outcomes in rectal cancer: an overview
The treatment protocols for rectal cancer continue to evolve, with increasing acceptance of a watch-and-wait policy for clinical complete responders to neoadjuvant chemoradiation therapy. It still, however, remains unclear who is likely to achieve a pathological complete response, which unequivocally portends a very favorable overall prognosis. Evolution of modern imaging techniques has paved the way for potential prediction of treatment response based on baseline, on-treatment, early post-treatment and subsequent follow-up imaging alone. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 20, 2018 Category: Cancer & Oncology Authors: Lakshmi Shree Mahadevan, James Zhong, BhanuPrasad Venkatesulu, Harmeet Kaur, Shreerang Bhide, Bruce Minsky, William Chu, Martijn Intven, Uulke A. van der Heide, Baukelien van Triest, Sunil Krishnan, William Hall Source Type: research

Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review
Colorectal cancer (CRC) is second most commonly diagnosed cancer in women and third in men and is responsible for almost 0.7 million deaths annually worldwide. (Torre et al., 2015) Recent data suggests a shift in incidence with a decreasing trend in patients over 50, and an increasing trend in those below 50. (Davis et al., 2011; Siegel et al., 2017) Early detection of CRC is associated with 5-year survival rates as high as 93% in patients staged T1/2N0M0. However, over 20% of patients present with metastatic disease at diagnosis, and up to half surgically radically treated patients will develop metastases. (Source: Critic...
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: J. Kobiela, P. Spychalski, G. Marvaso, D. Ciardo, V. Dell ’Acqua, F. Kraja, A. Błażyńska-Spychalska, A.J. Łachiński, A. Surgo, R. Glynne-Jones, B.A. Jereczek-Fossa Source Type: research

A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia
Anemia is a condition characterized by a deficiency of red blood cells (RBCs) or hemoglobin (Hb), resulting in a diminished capacity of the blood to carry and deliver oxygen to tissues and organs (Abbasi et al., 2014). Anemia is often multifactorial in etiology and may be patient- (e.g., iron-deficiencies, vitamin deficiencies), disease- (e.g., bone marrow diseases, chronic diseases, hemorrhage), or anticancer treatment- (e.g., chemotherapy, radiotherapy, precision therapies) related (Crathorne et al., 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: Luiz H. Arantes, Jeffrey Crawford, Pere Gascon, Mark Latymer, Vincent Launay-Vacher, Catherine Rolland, Florian Scotte, Jay Wish Source Type: research

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology
Developing nanoparticles to improve the specificity of anticancer agents towards tumor tissue and to better control drug delivery is a rising strategy in oncology. An increasing number of forms (e.g., conjugated nanoparticles, liposomes, immunoliposomes …) are now available on the shelves and numerous other scaffolds (e.g., dendrimeres, nanospheres, squalenes …) are currently at various stages of development. However, as of today most nanoparticles made available remain lipidic carriers. Pharmacokinetic variability is a major, yet largely under estimated issue with liposomal nanoparticles. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 19, 2018 Category: Cancer & Oncology Authors: Anne Rodallec, Sebastien Benzekri, Bruno Lacarelle, Joseph Ciccolini, Raphaelle Fanciullino Source Type: research

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
Since early 90  s platinum-based chemotherapy has been the mainstay of treatment for metastatic Non Small Cell Lung Cancer (NSCLC) (Non-small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002). However, during the last two decades front line treatment of metastatic NSCLC has profoundly changed mo ving from the old “one size fits all” concept to a “histology-based” approach and then, for a small subgroup of patients (i.e. EGFR mutated and ALK-rearranged NSCLCs), to a “molecularly-selected” one (Russo et al., 2015). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 15, 2018 Category: Cancer & Oncology Authors: A Russo, T Franchina, GRR Ricciardi, G Toscano, S Schifano, G Lo Certo, A Battaglia, E Pant ò, M Scaffidi Fonti, V Adamo Source Type: research

Immune check-point in cervical cancer
Cervical cancer (CC) is still one of the most commonly diagnosed cancer and one of the mainly leading cause of cancer death in female population (Siegel et al., 2017). Surgery, radiation therapy, chemotherapy or a combination of these therapeutic modalities represent the classical options to CC management (Anon, 2018; Marchetti et al., 2017). The appropriate strategy is based on tumor stage at diagnosis, but it remains dismal to improve survival in locally advanced or recurrent/metastatic disease (Pfaendler and Tewari, 2016). (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 15, 2018 Category: Cancer & Oncology Authors: F. De Felice, C. Marchetti, I. Palaia, R. Ostuni, L. Muzii, V. Tombolini, P. Benedetti Panici Source Type: research

Antiangiogenic therapy: markers of response, “normalization” and resistance
Currently in cancer treatment, one premise is to use antiangiogenic therapies in association with chemotherapy or radiotherapy to augment their efficacy by benefiting from the vascular “normalization” induced by antiangiogenic therapy. This concept defines the time during which the tumor blood vessels adopt normal-like morphology and functionality, i.e. the blood vessels become more mature, the perfusion augments and hypoxia decreases. To date, there is such a diversity of tre atment protocols where the type of antiangiogenic to adopt, its dose and duration of administration are different, that knowing when and how to ...
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Karima El Alaoui-Lasmaili, B éatrice Faivre Source Type: research

Radiation therapy in renal cell carcinoma
Traditionally, renal cell carcinoma (RCC) has been considered a radioresistant tumor and therefore radiation therapy (RT) was mainly confined in treatment of metastasis. New advances in RT techniques, including stereotactic irradiation, have made encouraging contributions in the oncologic scenario, opening up new opportunities in RCC management. (Source: Critical Reviews in Oncology Hematology)
Source: Critical Reviews in Oncology Hematology - June 12, 2018 Category: Cancer & Oncology Authors: Francesca De Felice, Vincenzo Tombolini Source Type: research